Polycystic Kidney Diseases
14
2
3
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
7.1%
1 terminated out of 14 trials
85.7%
-0.8% vs benchmark
0%
0 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (14)
Effects of Exogenous Ketosis on Proteinuria and Renal Function
The Factors Affecting IPP in Peritoneal Dialysis Patients with Polycystic Kidney Disease
Study and Management of Cystic Complications in Autosomal Dominant Polycystic Kidney Disease
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
ADPKD Patient Registry
The Association Between Skeletal Muscle Mass and Severity of Polycystic Liver Disease and Polycystic Kidney Disease
Pioglitazone and Lumbar Bone Marrow Fat in Chronic Kidney Disease
Assessing a Dose-Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients
Outcome of Autosomal Dominant Polycystic Kidney Disease Patients on Peritoneal Dialysis: a National Retrospective Study Based on Two French Registries (the French Language Peritoneal Dialysis Registry and the French Renal Epidemiology and Information Network).
Evaluation of Nephrectomy Specimen for Intracranial Aneurysm Development in ADPKD
Evaluation of Iliac and Renal Artery for Mechanism of Intracranial Aneurysm in ADPKD
Everolimus on CKD Progression in ADPKD Patients
Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Sirolimus for Massive Polycystic Liver